Worth reading
60In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
710000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Exercise status of the 22nd Series of Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clause)
発行・処分する株式数710,000Shares
710,000 new shares (shares delivered during the month)
Intended allottee
EVO FUND (placee)
発行済株式総数
4.4% (exercise ratio subject to the exercise restriction)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
¥101, ¥100, ¥95, ¥89, ¥86, ¥84, ¥81, ¥82, ¥79, ¥77, ¥75, ¥70, ¥67 and ¥68 (each exercise date in October 2026). The stock acquisition rights include a provision for adjustment of the exercise price. The adjustment floor is Not disclosed.
Number of Stock Acquisition Rights
Total issued: 241,250 rights; exercised during October 2026: 7,100 rights; unexercised as of 31 October 2026: 234,150 rights
Payment date
5 October 2026 (date of issuance of the stock acquisition rights)
Procedures under the Corporate Code of Conduct
The exercise ratio subject to the exercise restriction, 4.4%, is stated as the status of compliance with the exercise restriction under Article 434 of the Listing Regulations.
Most recent equity financing
5 October 2026: Issuance by third-party allotment of 241,250 Series 22 stock acquisition rights with an exercise-price adjustment provision (equivalent to 24,125,000 shares)
| Item | Details |
|---|---|
| Type of issuance or disposal | Exercise status of the 22nd Series of Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clause) |
| Number of shares to be issued or disposed of | 710,000 new shares (shares delivered during the month) |
| Payment date | 5 October 2026 (date of issuance of the stock acquisition rights) |
| Intended allottee | EVO FUND (placee) |
| Dilution Rate | 4.4% (exercise ratio subject to the exercise restriction) |
| Total number of issued shares | 16,116,527 shares (as of 5 October 2026) → Not disclosed |
| Exercise price | ¥101, ¥100, ¥95, ¥89, ¥86, ¥84, ¥81, ¥82, ¥79, ¥77, ¥75, ¥70, ¥67 and ¥68 (each exercise date in October 2026). The stock acquisition rights include a provision for adjustment of the exercise price. The adjustment floor is Not disclosed. |
| Number of Stock Acquisition Rights | Total issued: 241,250 rights; exercised during October 2026: 7,100 rights; unexercised as of 31 October 2026: 234,150 rights |
| Procedures under the Corporate Code of Conduct | The exercise ratio subject to the exercise restriction, 4.4%, is stated as the status of compliance with the exercise restriction under Article 434 of the Listing Regulations. |
| Most recent equity financing | 5 October 2026: Issuance by third-party allotment of 241,250 Series 22 stock acquisition rights with an exercise-price adjustment provision (equivalent to 24,125,000 shares) |
Items this document does not state (18)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company is reporting the monthly exercise status of its Series 22 stock acquisition rights in October 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.